Maryam Tabatabai, PharmD, vice president of clinical information, and Carole Kerzic, RPh, drug information pharmacist, share more about glucagon-like peptide-1 (GLP-1) receptor agonists in the drug...

Leading GLP-1 persistence, adherence and clinical outcomes research helps inform health plans and members

New resource page offers the latest GLP-1 insights, research and perspectives

New report details the latest on GLP-1s

Following real-world analysis of GLP-1 drugs for weight loss, Prime/Magellan Rx releases new video about GLP-1 research

Jessica Johnson, clinical consultant at Prime Therapeutics, shares more about common GLP-1 fraud schemes

Real-world study of GLP-1 patients continues to deliver leading insights

David Lassen, vice president of pharmacy clinical services, and Marci Chodroff, vice president and medical director at Prime Therapeutics, share more about the latest GLP-1 insights from ongoing...

Among the key findings from the study — among 4,066 members, Prime/MRx found 1 in 3 stayed on their GLP-1 and 27% took their medication as intended

Jessica Johnson, clinical consultant at Prime's Special Investigations Unit, shares how to identify fake GLP-1s

Ben Urick, senior director of health outcomes, and Landon Marshall, health outcomes research principal, share more about their educational session and research poster on GLP-1s

BioSpace: While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that myriad variables are causing patients to stop treatment

Real-world, integrated data follows-up on previous insights, analytics.

Jessica Johnson, clinical consultant, shares how the Special Investigations Unit at Prime helps identify cases of fraud

Managed Healthcare Executive: A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member,...

Urick, senior principal health outcomes researcher, shares more about his Spotlight Session at the Academy of Managed Care Pharmacy (AMCP)’s Annual Meeting

In this second of a two-part episode of the Pharmacy Friends podcast, industry experts discuss clinical evidence, drug information and appropriate patient selection for GLP-1 use

Event on Sept. 11 in Washington D.C. will feature the latest information on using GLP-1s to tackle the obesity epidemic.

What to expect at Academy of Managed Care Pharmacy (AMCP) Nexus 2023

Pat Gleason, assistant vice president, health outcomes, and David Eckwright, senior director, clinical project and program management, share an overview of Prime’s data and insights slated for this...

Prime to present seven studies and receive the 2024 JMCP Award for Excellence

The event emphasizes additional measures for obesity therapy.

Live updates from AMCP Annual Meeting

Forbes

Pharmacy Practice News, originally published by Specialty Pharmacy Continuum

BioSpace: As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health outcomes—evidenced by successful studies in therapeutic areas like...

As demand for GLP-1a drugs for weight loss has increased, new data provides additional insights about this new class of medications.

Specialty Pharmacy Continuum

Managed Healthcare Executive

Academy of Managed Care Pharmacy (AMCP)

BioPharma Dive: There are no drugs specifically for polycystic ovary syndrome, a chronic condition that can cause infertility. One study is testing whether Wegovy might be beneficial.

Prime/MRx remains at the forefront of GLP-1 research, presenting weight loss studies at this year’s annual meeting.

Lassen, chief clinical officer at Prime Therapeutics/Magellan Rx, shares insights on GLP-1 weight-loss drugs and evidence-based approaches to providing the kind of care we’d want for our loved ones.

Studies include Prime’s GLP-1 obesity research, the impact of social determinants of health and more.

Star Tribune

Shortages in the manufacturing chain have led to label hopping and an increase in off-label use

The American Journal of Managed Care (AJMC): The growing list of insurers dropping coverage for costly GLP-1 weight loss drugs leaves patients to bear even higher out-of-pocket expenses while still...

Managed Healthcare Executive: Use of GLP-1 drugs and weight-loss care management programs need to focus on adherence and persistency for better health outcomes, suggests Prime...

CNN: At 37:03, listen to fitness expert Jillian Michaels cite Prime/Magellan Rx research on a podcast recording of a June 21 CNN broadcast

Report encourages providers to consider health contexts and lifestyle modifications as well as personal preferences and current guidelines when prescribing GLP-1s for weight loss

Academy of Managed Care Pharmacy (AMCP)'s Annual Meeting gathers thousands of health plan, pharmacy benefit management and biopharmaceutical experts to help define the future of managed care pharmacy.

From research posters and education sessions to the Pharmacy Friends podcast, Prime has you covered on the latest managed care pharmacy insights

Prime’s industry-leading research on GLP-1s was recognized at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting in Houston

Forbes

U.S. News & World Report

Forbes

A roundup of Prime's award-winning presentations and insights at AMCP Annual Meeting in Houston

In this episode, Prime/MRx clinicians — along with special guests — discuss the hottest topics covered at the Academy of Managed Care Pharmacy (AMCP)'s 2024 Annual Meeting in New Orleans

Journal of Managed Care & Specialty Pharmacy (JMCP)

Hear some of the latest insights from the annual managed care pharmacy event, where Prime Therapeutics clinical and health outcomes teams presented leading research findings

Identifying and managing diabetes and weight loss therapies earns AMCP platinum award

Annual conference gathers 2,500+ managed care leaders to discuss complex health care issues.

Managed Healthcare Executive

USA Today

Reuters

Insider

CNBC

Formulary Watch

Star Tribune

Business Insider